American CryoStem

03/04/2022

American CryoStem Announces Patient Treatment Status for its Phase I Clinical Trial for Post-Concussion Syndrome (PCS)

03/11/2021

American CryoStem Corporation (OTC: CRYO) a clinical stage biotechnology company, global licensor and a pioneer in autologous cellular processing and therapies announced today that it has begun processing patient's adipose tissue and culturing mesenchymal stem cells (ATCell™), for use in its FDA approved IND Phase I Clinical Trial.

American CryoStem and BioTherapeutic Labs Corp. Enter into R&D, Collaboration and Marketing Agreement

02/25/2021

American CryoStem and BioTherapeutic Labs Corp. Enter into R&D, Collaboration and Marketing Agreement... CRYO will optimize cell recovery from the umbilical cord to supply umbilical cord cells under its previously announced “CRADA” agreement with the Biomedical Research Laboratory in Bethesda, Maryland, and for future IND application(s).

FDA clearer CRYO or phase 1 clinical study

01/06/2021

Proud to announce the following: American CryoStem Enters into a Cooperative Research and Development Agreement (CRADA) to Develop Standardized Treatment Protocols

FDA clearer CRYO or phase 1 clinical study

12/01/2020

American CryoStem Corporation (OTC PINK: CRYO) a clinical stage biotechnology company, global licensor and a pioneer in autologous cellular processing and therapies announced today that it has commenced recruiting subjects for its IND Phase I Clinical Trial and added an additional sub-investigator to the ATCELL™ Clinical Trial team.

FDA clearer CRYO or phase 1 clinical study

09/23/2020

American CryoStem Announces: FDA has cleared its Investigational New Drug (IND) for Post-Concussion Syndrome for Phase I Clinical Trial

FDA clearer CRYO or phase 1 clinical study

09/19/2019

"The FDA’s acceptance for review of American CryoStem’s IND application is a significant milestone for the Company and represents a meaningful step forward in the treatment of patients suffering from Post Concussion Syndrome (“PCS”), and for the advancement of Regenerative Medicine. We are now one step closer to obtaining approval to treat patients with a cellular therapy derived from the patient's own adipose tissue"

EATONTOWN, NJ / ACCESSWIRE / September 18, 2019 / American CryoStem Corporation (OTC PINK: CRYO) a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular products and technologies for the Regenerative and Personalized Medicine industries, announced today....

03/20/2019

We are pleased to continue the growth of our ATGRAFT market presence with our partners in Japan by working with the largest chain of plastic surgery clinics, Shonan Beauty Clinic. For further information please read our press release below.

EATONTOWN, NJ / ACCESSWIRE / March 20, 2019 / American CryoStem Corporation (OTC PINK: CRYO) a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular products and technologies for the Regenerative and Personalized Medicine industries, today announced that...

07/12/2018

EATONTOWN, NJ / ACCESSWIRE / July 12, 2018 / American CryoStem Corporation (OTC PINK: CRYO), a leading strategic application developer, marketer, and global licensor of patented adipose tissue-based cellular technologies, for the Regenerative and Personalized Medicine industries, today announced the...

07/12/2018

American CryoStem is one of the largest commercial personal globally, Announces Launch of ATGRAFT™ in China (OTC: )
to leading and
https://www.latestpr.com/companys-news/american-cryostem-announces-launch-of-atgraft-in-china/

06/22/2018

American CryoStem CEO John Arnone and COO introduce ATGRAFT on behalf of licensee Baoxin to MOII cosmetic hospital in Shenzhen, China.